A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic ProteinsAndrzej Kierzek, Piet H. van der Graaf, Timothy P. Hickling et al.|CPT Pharmacometrics & Systems Pharmacology|2019Cited by 34
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patientsYuqin Song, Jun Zhu, Qingyuan Zhang et al.|Journal of Cancer Research and Therapeutics|2024Cited by 2
[A study of the efficacy and safety of using hepatitis B surface antigen-positive donors for liver transplantation].Wei Ju, Jie Huang, Xiao Shun He et al.|PubMed|2012Cited by 1
P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLINGKevin C. Hart, Maya F. Kotturi, Maya K. Leabman et al.|HemaSphere|2023Cited by 0